These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 9881060)
21. Antithrombotic and antiplatelet activities of 2-chloro-3-[4-(ethylcarboxy)-phenyl]-amino-1,4-naphthoquinone (NQ12), a newly synthesized 1,4-naphthoquinone derivative. Yuk DY; Ryu CK; Hong JT; Chung KH; Kang WS; Kim Y; Yoo HS; Lee MK; Lee CK; Yun YP Biochem Pharmacol; 2000 Oct; 60(7):1001-8. PubMed ID: 10974210 [TBL] [Abstract][Full Text] [Related]
22. New no-donors with antithrombotic and vasodilating activities, X: Antiplatelet and antithrombotic effects of 3-methylsydnone-5-nitrosimine (RE 2047) in combination with ASA, pentoxifylline, and ticlopidine. Rehse K; Ciborski T Arch Pharm (Weinheim); 1995 Jan; 328(1):71-8. PubMed ID: 7695475 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and antiplatelet effects of the new antithrombotic agent aspalatone with low ulcerogenicity. Han BH; Suh DY; Yang HO; Park YH; Kang YH; Kim YC Arzneimittelforschung; 1994 Oct; 44(10):1122-6. PubMed ID: 7818584 [TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and evaluation of nitric oxide releasing derivatives of 3-n-butylphthalide as antiplatelet and antithrombotic agents. Wang X; Li Y; Zhao Q; Min Z; Zhang C; Lai Y; Ji H; Peng S; Zhang Y Org Biomol Chem; 2011 Aug; 9(16):5670-81. PubMed ID: 21706121 [TBL] [Abstract][Full Text] [Related]
25. Studies on the synthesis of some xanthonoid derivatives possessing antiplatelet effects. Lin CN; Fang SC; Lin HC; Ko FN; Shieh BJ; Liu HW; Teng CM J Pharm Pharmacol; 1994 Nov; 46(11):917-21. PubMed ID: 7897599 [TBL] [Abstract][Full Text] [Related]
26. New antithrombotics with an indazole structure. Yildiz AK; Rehse K; Stasch JP; Bischoff E Arch Pharm (Weinheim); 2004 Jun; 337(6):311-6. PubMed ID: 15188220 [TBL] [Abstract][Full Text] [Related]
27. Synthesis and pharmacological evaluation of pyrroloazepine derivatives as potent antihypertensive agents with antiplatelet aggregation activity. Mizuno A; Inomata N; Miya M; Kamei T; Shibata M; Tatsuoka T; Yoshida M; Takiguchi C; Miyazaki T Chem Pharm Bull (Tokyo); 1999 Feb; 47(2):246-56. PubMed ID: 10071857 [TBL] [Abstract][Full Text] [Related]
28. New NO-donors with antithrombotic and vasodilating activities, V: Oligonitroso sydnone imines. Rehse K; Schleifer KJ; Martens A; Kämpfe M Arch Pharm (Weinheim); 1994 Jun; 327(6):393-7. PubMed ID: 8048846 [TBL] [Abstract][Full Text] [Related]
29. Improving upon the in vitro biological activity of antithrombotic disulfides. MacDonald JA; Marchand ME; Langler RF Blood Coagul Fibrinolysis; 2004 Sep; 15(6):447-50. PubMed ID: 15311152 [TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and biological evaluation of hydrogen sulfide releasing derivatives of 3-n-butylphthalide as potential antiplatelet and antithrombotic agents. Wang X; Wang L; Sheng X; Huang Z; Li T; Zhang M; Xu J; Ji H; Yin J; Zhang Y Org Biomol Chem; 2014 Aug; 12(31):5995-6004. PubMed ID: 24988475 [TBL] [Abstract][Full Text] [Related]
31. Conformationally restricted congeners of hypotensive and platelet aggregation inhibitors: 6-aryl-5-methyl-4,5-dihydro-3(2H)-pyridazinones derived from 5H-indeno[1,2-c]pyridazine. Cignarella G; Barlocco D; Pinna GA; Loriga M; Tofanetti O; Germini M; Sala F J Med Chem; 1986 Nov; 29(11):2191-4. PubMed ID: 3783580 [TBL] [Abstract][Full Text] [Related]
32. [Synthesis and antithrombotic activity of acetylsalicyl ferulic acid-coupling furoxans and nitrates]. Zhou Z; Jiang LY; Zhang YH; Ji H; Sun Y; Peng SX Yao Xue Xue Bao; 2006 Nov; 41(11):1050-6. PubMed ID: 17262946 [TBL] [Abstract][Full Text] [Related]
33. Antithrombotic effects of the novel inhibitor of thrombin-induced offtelet aggregation and thrombus formation, 3-[2-[1,1':2',1"]-terphenyl-4'-yl)ethyl]phenoxyacetic acid. Miyamae T; Hashizume H; Ogawa T; Okayama T; Nukui E; Oshima K; Morikawa T; Hagiwara M Arzneimittelforschung; 1997 Jan; 47(1):13-8. PubMed ID: 9037437 [TBL] [Abstract][Full Text] [Related]
35. Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative. Jin YR; Hwang KA; Cho MR; Kim SY; Kim JH; Ryu CK; Son DJ; Park YH; Yun YP Vascul Pharmacol; 2004 Feb; 41(1):35-41. PubMed ID: 15135330 [TBL] [Abstract][Full Text] [Related]
36. Discovery of novel, potent, isosteviol-based antithrombotic agents. Chen P; Zhang D; Li M; Wu Q; Lam YPY; Guo Y; Chen C; Bai N; Malhotra S; Li W; O'Connor PB; Fu H Eur J Med Chem; 2019 Dec; 183():111722. PubMed ID: 31563807 [TBL] [Abstract][Full Text] [Related]
37. Synthesis, antiplatelet and antithrombotic activities of resveratrol derivatives with NO-donor properties. Dutra LA; Guanaes JFO; Johmann N; Lopes Pires ME; Chin CM; Marcondes S; Dos Santos JL Bioorg Med Chem Lett; 2017 Jun; 27(11):2450-2453. PubMed ID: 28400236 [TBL] [Abstract][Full Text] [Related]
38. [2-(O-Phenylalkyl)phenoxy]alkylamines III: Synthesis and selective serotonin-2 receptor binding (2). Tanaka N; Goto R; Ito R; Hayakawa M; Sugidachi A; Ogawa T; Asai F; Fujimoto K Chem Pharm Bull (Tokyo); 2000 Nov; 48(11):1729-39. PubMed ID: 11086903 [TBL] [Abstract][Full Text] [Related]
39. Interaction of Viagra with the NO donors molsidomine and RE 2047 with regard to antithrombotic and blood pressure lowering activities. Rehse K; Scheffler H; Reitner N Arch Pharm (Weinheim); 1999 May; 332(5):182-4. PubMed ID: 10366905 [TBL] [Abstract][Full Text] [Related]
40. New NO-donors with antithrombotic and vasodilating activities, Part 20. Azodioxides activated by electron acceptors in geminal or vicinal position. Rehse K; Herpel M Arch Pharm (Weinheim); 1998 Mar; 331(3):104-10. PubMed ID: 9557136 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]